



FEP Medical Policy Manual

FEP 1.01.09 Transcutaneous Electrical Nerve Stimulation and Transcutaneous Afferent Patterned Stimulation

Annual Effective Policy Date: April 1, 2026

Original Policy Date: September 2012

Related Policies:

1.01.24 - Interferential Current Stimulation

2.01.21 - Temporomandibular Joint Disorder

7.01.29 - Percutaneous Electrical Nerve Stimulation, Percutaneous Neuromodulation Therapy, and Restorative Neurostimulation Therapy

Transcutaneous Electrical Nerve Stimulation and Transcutaneous Afferent Patterned Stimulation

Description

Description

Transcutaneous electrical nerve stimulation and transcutaneous afferent patterned stimulation are noninvasive neuromodulation techniques that involve the application of electrical stimulation to the surface of the skin. In addition to more traditional settings such as a physician's office or an outpatient clinic, these techniques can be self-administered in an individual's home.

OBJECTIVE

The objective of this evidence review is to determine whether the application of transcutaneous electrical nerve stimulation or transcutaneous afferent patterned stimulation improve the net health outcome in individuals with a variety of health conditions including chronic and/or acute pain, essential tremor, action tremor due to Parkinson disease, migraine, and attention deficit hyperactivity disorder.

POLICY STATEMENT

A trial of transcutaneous electrical nerve stimulation (TENS) of at least 30 days may be considered **medically necessary** to establish efficacy for the management of refractory chronic pain (eg, chronic musculoskeletal pain or neuropathic pain) that causes significant disruption of function when the following conditions have been met:

- The pain is unresponsive to at least 3 months of conservative medical therapy; and
- The trial is monitored by a physician.

Continued use of TENS may be considered **medically necessary** for treatment of refractory chronic pain (eg, chronic musculoskeletal or neuropathic pain) that causes significant disruption of function when the following conditions have been met:

- Efficacy has been demonstrated in an initial therapeutic trial (see Policy Guidelines section); and
- Compliance has been demonstrated in the therapeutic trial with the device used on a regular basis (eg, daily or near daily use) throughout the trial period.

TENS is considered **investigational** for the management of acute pain (eg, postoperative or during labor and delivery).

TENS is considered **investigational** for the prevention or treatment of migraine headache.

TENS is considered **investigational** for the management of attention deficit hyperactivity disorder.

Transcutaneous afferent patterned stimulation (TAPS) is considered **investigational** for the following conditions:

- Essential tremor;
- Action tremor for Parkinson disease.

The use of TENS or TAPS for any other condition, including but not limited to the treatment of dementia is considered **investigational**.

POLICY GUIDELINES

For the purposes of these policy guidelines, refractory chronic pain is defined as pain that causes significant disruption of function and has not responded to at least 3 months of conservative therapy, including nonsteroidal anti-inflammatory medications, ice, rest, and/or physical therapy.

Documentation for the trial should include:

- Initial assessment/evaluation of the nature, duration, and perceived intensity of pain;
- The types and duration of prior treatments;
- Treatment plan including ongoing medications and proposed use of transcutaneous electrical nerve stimulation (TENS) unit, including the frequency and duration of treatment.

Clinical summary of the trial to determine efficacy should include:

- Perceived intensity of pain with and without TENS (eg, 2-point or 30% improvement in visual analog scale);
- Ongoing medication requirements for pain relief (if any);
- Other modalities (if any) in use for pain control;
- Actual use of TENS on a daily basis (frequency and duration of application).

TENS devices may be delivered through a practitioner and require a prescription or obtained without a prescription. It is possible that prescribed devices provide higher intensity stimulation than units sold directly to the public.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

State or federal mandates (eg, Federal Employee Program) may dictate that certain U.S. Food and Drug Administration approved devices, drugs, or biologics may not be considered investigational, and thus these devices may be assessed only by their medical necessity.

FDA REGULATORY STATUS

TENS devices consist of an electrical pulse generator, usually battery-operated, connected by wire to 2 or more electrodes, which are applied to the surface of the skin at the site of the pain. Since 1977, a large number of devices have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process. Marketing clearance via the 510(k) process does not require data on clinical efficacy; as a result, these cleared devices are considered substantially equivalent to predicate devices marketed in interstate commerce before May 1976, the enactment date of the Medical Device Amendments. The cleared devices are also equivalent to devices that have been reclassified and do not require a premarket approval application. FDA product code: GZJ.

In 2014, the Cefaly (STX-Med), which is a TENS device, was granted a de novo 510(k) classification by the FDA for the prophylactic treatment of migraine in patients 18 years of age or older.¹ The Cefaly Acute and Cefaly Dual devices were cleared by the FDA through the 510(k) process for the acute treatment of migraine in patients in 18 years of age or older and for both the acute treatment and prophylaxis of migraines in adults, respectively, in 2017.^{2,3} Other TENS devices cleared by the FDA through the 510(k) process for the prophylactic treatment of migraine in patients include Allive (Nu Eyne Co), Relivion (Leurolief Ltd.) and HeadTerm (EEspress) among others.^{4,5,6} FDA product code: PCC.

In 2018, the FDA reviewed the Cala ONE™ TENS device (Cala Health) via the de novo pathway and granted approval for the device as an aid in the transient relief of hand tremors following stimulation in the affected hand of adults with essential tremor. This prescription device is contraindicated for use in patients with an implanted electrical medical device, those that have suspected or diagnosed epilepsy or other seizure disorder, those who are pregnant, and patients with swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions. In October 2020, the FDA granted breakthrough device designation to the Cala Trio™ device for the treatment of action tremors in the hands of adults with Parkinson's disease.⁷ In November 2022, the Cala kIQ™ device was approved via the 510(k) pathway (K222237). The device is indicated to aid in the temporary relief of hand tremors in the treated hand following stimulation in adults with essential tremor. It was also approved to aid in the temporary relief of postural and kinetic hand tremor symptoms that impact some activities of daily living in the treated hand of adults with Parkinson's disease. Cala Trio and Cala kIQ use TAPS therapy which consists of bursts of non-invasive electrical stimulation applied to the median and radial nerves.

In 2019, the FDA permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD) - the Monarch external Trigeminal Nerve Stimulation (eTNS) System by NeuroSigma.⁸ The FDA reviewed the system through the de novo premarket review pathway. This prescription only TENS device is indicated for patients 7 to 12 years of age who are not currently taking prescription ADHD medication. The Monarch eTNS System is intended to be used in the home under the supervision of a caregiver. The device generates a low-level electrical pulse and connects via a wire to a small patch that adheres to a patient's forehead, just above the eyebrow.

In 2021, the FDA approved the Axon Therapy device (Neuralace Medical, Inc.) for marketing through the 510(k) process for relief of chronic, intractable postsurgical or posttraumatic pain in adults.⁹ The Axon Therapy device is an electromagnetic transcutaneous peripheral nerve stimulator. FDA product codes: QPL, IPF.

RATIONALE

Summary of Evidence

For individuals who have chronic pain (eg, musculoskeletal, neuropathic, and mixed pain conditions) who receive transcutaneous electrical nerve stimulation (TENS), the evidence includes numerous randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life (QOL), and medication use. The overall strength of the evidence is weak. The best evidence exists for the treatment

of chronic, intractable pain. Available evidence indicates that TENS can improve chronic intractable pain in some patients, and there is support for its use in clinical guidelines by specialty societies. To best direct TENS toward patients who will benefit, a short-term trial of TENS is appropriate, with continuation only in patients who show an initial improvement. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have acute pain (eg, surgical, musculoskeletal, labor, and mixed pain conditions) who receive TENS, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. Overall, evidence for the use of TENS from high-quality trials remains inconclusive for most indications. A systematic review of TENS for acute and chronic pain found some evidence that TENS reduces pain intensity over and above that seen with placebo and other control groups in patients with acute pain, but small-sized trials contributed to imprecision in magnitude estimates. Systematic reviews have found that TENS may help reduce pain in patients with post-operative pain (post-caesarean and total knee arthroplasty), dysmenorrhea, and pain associated with labor and delivery. For low back pain, systematic reviews have found insufficient evidence to support or refute the use of TENS. Randomized controlled trials have reported mixed results in the efficacy of TENS across various acute pain conditions. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have essential tremor who receive transcutaneous afferent patterned stimulation (TAPS), the evidence includes a pragmatic RCT, a nonrandomized, prospective study, and a retrospective database study. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. Although the RCT indicated reduced tremor power among patients receiving TAPS, the trial lacked thorough analysis of clinically relevant outcomes, was open-label, and short-term. Results from the nonrandomized study suggest that TAPS therapy is effective and safe for patients with essential tremor. However, the trial was limited by its open-label, single-arm design, lack of defined standards for what constitutes a clinically meaningful improvement in stated endpoints, and exclusion of patients who exited the study early from the pre-specified primary and secondary endpoint analyses. Further studies comparing TAPS to standard of care therapy for essential tremor are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have action tremor associated with Parkinson disease who receive TAPS, the evidence includes a prospective, open-label, single-arm study. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. Results of the prospective trial suggest that repeated in-home TAPS therapy is effective for reducing tremor power and safe for patients with essential tremor. Limitations identified were the open-label, single-arm design, and lack of long-term outcomes. Further studies comparing TAPS to pharmacologic therapy for tremor associated with Parkinson disease are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have attention deficit hyperactivity disorder (ADHD) who receive TENS, the evidence includes an RCT. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. Results of the RCT concluded that TENS is an effective and safe treatment option for pediatric patients with ADHD. However, the study included a small patient sample and was of short duration. Further studies comparing TENS to standard of care therapy for ADHD are needed. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have chronic or episodic migraine who receive TENS for treatment of acute migraine, the evidence includes 3 double-blind, sham-controlled RCTs. Two of the RCTs evaluated healthcare-provider administration of a TENS device during a single episode in emergency departments, and 1 evaluated self-administration of the device at home during acute episodes over a 3-month period. The studies conducted in emergency departments showed clinically and statistically significant reductions in pain intensity and medication use within 2 hours of use. The self-administration study had mixed results: The difference in median pain scores before and after treatment was significantly higher in the TENS group at months 1 and 2, but at month 3 the difference was not statistically significant. Function and analgesic medication use did not differ between groups at any time point. Strengths of the RCTs included the use of a sham device and blinded outcome assessment using validated outcome measures. Although short-term pain relief was demonstrated at some time points, the quality of the overall body of evidence was downgraded due to inconsistency of results and heterogeneity in study settings. It is not clear whether the pain intensity reductions demonstrated in emergency department settings would generalize to other settings over longer time periods. Supporting evidence from RCTs is needed. Additionally, based on the existing evidence, it is unclear how TENS would fit into the current migraine treatment pathway, although it could provide benefit for those who do not receive adequate benefit from pharmacologic first- or second-line therapies, or who may have a contraindication to pharmacologic therapies. The specific intended use must be specified in order to adequately evaluate net health benefit. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have chronic or episodic migraine who receive TENS for migraine prevention, the evidence includes 1 RCT. Relevant outcomes are symptoms, functional outcomes, QOL, and medication use. The RCT (N=67) reported a greater proportion of participants achieving at least a 50% reduction in migraines with TENS than with sham placebo and modest reductions in the number of total headache and migraine days. In the intention-to-treat analysis, the reduction in the number of migraine days (run-in vs. 3-months) was not statistically significant. The proportion of responders ($\geq 50\%$ reduction in the number of migraine days/month) significantly higher in the TENS group. The number of migraine attacks from the run-in period to the 3-month evaluation, number of headache days, and antimigraine medication use were significantly lower for the active TENS group. The severity of migraine days did not differ significantly between groups. This manufacturer-sponsored trial needs corroboration before conclusions can be made with certainty about the efficacy of TENS for preventing migraine headaches. Additionally, based on the existing evidence, it is unclear how TENS would fit into the current migraine prevention pathway, although it could provide benefit for those who do not receive adequate benefit from pharmacologic first- or second-line therapies, or who may have a contraindication to pharmacologic therapies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in "Supplemental Information" if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Academy of Neurology

In 2010, the American Academy of Neurology published an evidence-based review of the efficacy of transcutaneous electrical nerve stimulation (TENS) for the treatment of pain in neurologic disorders.³³ The Academy did not recommend TENS for the treatment of chronic low back pain due to lack of proven efficacy (level A, established evidence from 2 class I studies), but stated that TENS should be considered for the treatment of painful diabetic neuropathy (level B, probably effective, based on 2 class II studies).

American College of Rheumatology

In 2019, the American College of Rheumatology made a strong recommendation against the use of TENS for knee and hip osteoarthritis.¹¹⁹

American College of Obstetricians and Gynecologists

In 2019 (reaffirmed in 2025), the American College of Obstetricians and Gynecologists (ACOG) guidelines on labor and delivery found that TENS may "help women cope with labor more than directly affect pain scores."¹²⁰

American Society of Anesthesiologists, et al

In 2010, the practice guidelines from the American Society of Anesthesiologists and American Society of Regional Anesthesia and Pain Medicine recommended that TENS be used as part of a multimodal approach to management for patients with chronic back pain and may be used for other pain conditions (eg, neck and phantom limb pain).¹²¹

In 2016, American Society of Anesthesiologists, American Pain Society, and the American Society of Regional Anesthesia and Pain Medicine, published guidelines on the management of postoperative pain.¹²² With regards to TENS, the groups made the following relevant recommendation:

- "The panel recommends that clinicians consider TENS as an adjunct to other postoperative pain treatments (weak recommendation, moderate-quality evidence)."

National Cancer Institute

The National Cancer Institute's Physician Data Query identifies TENS as a potential nonpharmacological modality for pain control for postthoracotomy pain syndrome.¹²³

National Comprehensive Cancer Network

National Comprehensive Cancer Network guidelines on adult cancer pain (v.2.2025) indicate that nonpharmacologic interventions, including TENS, may be considered in conjunction with pharmacologic interventions as needed (category 2A).¹²⁴

National Institute for Health and Care Excellence

In 2016 (updated 2020), the NICE guidance on low back pain indicated that, despite the long history of use of TENS for back pain, the quality of research studies is poor. This guidance recommended against TENS as a treatment.¹²⁵

In 2014, the NICE guidance on osteoarthritis care and management in adults indicated that TENS be considered "as an adjunct to core treatments for pain relief." In 2022, NICE osteoarthritis guidelines recommend against TENS for osteoarthritis.¹²⁶

In 2017, the NICE guidance on intrapartum care recommended against the use of TENS for "established labour." In 2023, NICE recommendations for TENS included "there is very little evidence of its effectiveness in established labour, but no evidence of harm."¹²⁷

North American Spine Society

In 2020, the North American Spine Society clinical guidelines on the diagnosis and treatment of low back pain provided guidance on the effectiveness of different physical medicine and rehabilitation therapies.¹²⁸ The guideline noted that there is conflicting evidence that TENS results in improvement in pain or function at short- to medium-term follow-up. The work group further recommended that randomized clinical trials with long-term follow-up are needed to evaluate the benefits of TENS compared to exercise/physical therapy or as adjunctive use to usual care for low back pain.

In 2011, the North American Spine Society clinical guidelines on the diagnosis and treatment of cervical radiculopathy from degenerative disorders discussed the role of ancillary treatments such as bracing, traction, electrical stimulation, acupuncture, and TENS.¹²⁹ A consensus statement from the Society recommended that ozone injections, cervical halter traction, and combinations of medications, physical therapy, injections, and traction have been associated with improvements in patient-reported pain in uncontrolled case series. Such modalities may be considered, recognizing that no improvement relative to the natural history of cervical radiculopathy has been demonstrated. There were no specific statements about the role of TENS in this population.

Osteoarthritis Research Society International

In 2014, the guidelines from the Osteoarthritis Research Society International recommended that TENS was inappropriate for use in patients with multi-joint osteoarthritis; moreover, the guidelines suggested that TENS has an uncertain value for the treatment of knee-only osteoarthritis pain.¹³⁰ Updated guidance (2019) on the non-surgical management of knee, hip, and polyarticular osteoarthritis does not address TENS nor include it in their patient-focused treatment recommendations.¹³¹

Society of Cardiovascular Anesthesiologists

The Society of Cardiovascular Anesthesiologists published a practice advisory in 2025 for postoperative pain management of thoracic surgical patients.¹³² Recommendations relevant to TENS included the following:

- "TENS therapy can be used as an adjunct to multimodal analgesia for reducing pain and opioid consumption after thoracotomy.
- The role of TENS therapy as an adjunct to the multimodal analgesic regimen in reducing pain after video assisted thoracoscopic surgery is uncertain at this time."

World Health Organization

In 2023, the World Health Organization recommended against the use of TENS as part of routine care for patients with chronic low back pain.¹³³ They found the net benefits across outcomes and comparators to be small or uncertain.

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

The Centers for Medicare & Medicaid Services currently have a number of national coverage decisions on TENS.^{134,135,136} The different coverage decisions address the use of TENS in the treatment of chronic intractable pain, noncoverage of TENS for chronic low back pain except to conduct

research for said indication, and coverage for acute postoperative pain.

REFERENCES

1. Food and Drug Administration. De Novo Classification Request for Cefaly Device. 2012; http://www.accessdata.fda.gov/cdrh_docs/reviews/K122566.pdf. Accessed November 3, 2025.
2. Food and Drug Administration. Cefaly Dual Device: K173006. 2017; https://www.accessdata.fda.gov/cdrh_docs/pdf17/K173006.pdf. Accessed November 4, 2025.
3. Food and Drug Administration. Cefaly Acute Device: K171446. 2017; https://www.accessdata.fda.gov/cdrh_docs/pdf17/K171446.pdf. Accessed November 5, 2025.
4. Food and Drug Administration. HeadTerm Device: K172450. 2018; https://www.accessdata.fda.gov/cdrh_docs/pdf17/K172450.pdf. Accessed November 2, 2025.
5. Food and Drug Administration. Allive Device: K192773. 2019; https://www.accessdata.fda.gov/cdrh_docs/pdf19/K192773.pdf. Accessed November 7, 2025.
6. Food and Drug Administration. Relivion Device: K203419. February 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf20/K203419.pdf. Accessed November 1, 2025.
7. Cala Health news release. Cala Health receives FDA breakthrough device designation for Cala Trio therapy to treat action tremors in Parkinson's disease. <https://www.businesswire.com/news/home/20201022005276/en/Cala-Health-Receives-FDA-Breakthrough-Device-Designation-for-Cala-Trio%E2%84%A2-Therapy-to-Treat-Action-Tremors-in-Parkinsons-Disease>. Accessed November 7, 2025.
8. FDA news release. FDA permits marketing of first medical device for treatment of ADHD. April 19, 2019. <https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-first-medical-device-treatment-adhd>. Accessed November 7, 2025.
9. Food and Drug Administration. Axon Therapy Device: K210021. 2021; https://www.accessdata.fda.gov/cdrh_docs/pdf21/K210021.pdf. Accessed November 6, 2025.
10. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). TENS or PENS in the treatment of chronic and postoperative pain. TEC Assessments. 1996; Volume 11, Tab 21. PMID
11. Bronfort G, Nilsson N, Haas M, et al. Non-invasive physical treatments for chronic/recurrent headache. *Cochrane Database Syst Rev.* 2004; (3): CD001878. PMID 15266458
12. Brosseau L, Judd MG, Marchand S, et al. Transcutaneous electrical nerve stimulation (TENS) for the treatment of rheumatoid arthritis in the hand. *Cochrane Database Syst Rev.* 2003; 2003(3): CD004377. PMID 12918009
13. Brosseau LU, Pelland LU, Casimiro LY, et al. Electrical stimulation for the treatment of rheumatoid arthritis. *Cochrane Database Syst Rev.* 2002; 2002(2): CD003687. PMID 12076504
14. Cameron M, Lonergan E, Lee H. Transcutaneous electrical nerve stimulation (TENS) for dementia. *Cochrane Database Syst Rev.* 2003; 2003(3): CD004032. PMID 12917999
15. Carroll D, Moore RA, McQuay HJ, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. *Cochrane Database Syst Rev.* 2001; (3): CD003222. PMID 11687055
16. Dowswell T, Bedwell C, Lavender T, et al. Transcutaneous electrical nerve stimulation (TENS) for pain relief in labour. *Cochrane Database Syst Rev.* Apr 15 2009; (2): CD007214. PMID 19370680
17. Hurlow A, Bennett MI, Robb KA, et al. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. *Cochrane Database Syst Rev.* Mar 14 2012; 2012(3): CD006276. PMID 22419313
18. Khadilkar A, Milne S, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain. *Cochrane Database Syst Rev.* Jul 20 2005; (3): CD003008. PMID 16034883
19. Khadilkar A, Odebiyi DO, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) versus placebo for chronic low-back pain. *Cochrane Database Syst Rev.* Oct 08 2008; 2008(4): CD003008. PMID 18843638
20. Kroeling P, Gross A, Goldsmith CH, et al. Electrotherapy for neck pain. *Cochrane Database Syst Rev.* Oct 07 2009; (4): CD004251. PMID 19821322
21. Martimbianco ALC, Porfrio GJ, Pacheco RL, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic neck pain. *Cochrane Database Syst Rev.* Dec 12 2019; 12(12): CD011927. PMID 31830313
22. Milne S, Welch V, Brosseau L, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic low back pain. *Cochrane Database Syst Rev.* 2001; (2): CD003008. PMID 11406059
23. Mulvey MR, Bagnall AM, Johnson MI, et al. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. *Cochrane Database Syst Rev.* May 12 2010; (5): CD007264. PMID 20464749
24. Nnoaham KE, Kumbang J. Transcutaneous electrical nerve stimulation (TENS) for chronic pain. *Cochrane Database Syst Rev.* Jul 16 2008; (3): CD003222. PMID 18646088
25. Osiri M, Welch V, Brosseau L, et al. Transcutaneous electrical nerve stimulation for knee osteoarthritis. *Cochrane Database Syst Rev.* 2000; (4): CD002823. PMID 11034768
26. Price CI, Pandyan AD. Electrical stimulation for preventing and treating post-stroke shoulder pain. *Cochrane Database Syst Rev.* 2000; 2000(4): CD001698. PMID 11034725
27. Proctor ML, Smith CA, Farquhar CM, et al. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. *Cochrane Database Syst Rev.* 2002; 2002(1): CD002123. PMID 11869624

28. Robb KA, Bennett MI, Johnson MI, et al. Transcutaneous electric nerve stimulation (TENS) for cancer pain in adults. *Cochrane Database Syst Rev.* Jul 16 2008; (3): CD006276. PMID 18646140
29. Rutjes AW, Nesch E, Sterchi R, et al. Transcutaneous electrostimulation for osteoarthritis of the knee. *Cochrane Database Syst Rev.* Oct 07 2009; 2009(4): CD002823. PMID 19821296
30. Walsh DM, Howe TE, Johnson MI, et al. Transcutaneous electrical nerve stimulation for acute pain. *Cochrane Database Syst Rev.* Apr 15 2009; (2): CD006142. PMID 19370629
31. Zimpel SA, Torloni MR, Porfrio GJ, et al. Complementary and alternative therapies for post-caesarean pain. *Cochrane Database Syst Rev.* Sep 01 2020; 9(9): CD011216. PMID 32871021
32. Verville L, Hincapi CA, Southerst D, et al. Systematic Review to Inform a World Health Organization (WHO) Clinical Practice Guideline: Benefits and Harms of Transcutaneous Electrical Nerve Stimulation (TENS) for Chronic Primary Low Back Pain in Adults. *J Occup Rehabil.* Dec 2023; 33(4): 651-660. PMID 37991646
33. Dubinsky RM, Miyasaki J. Assessment: efficacy of transcutaneous electric nerve stimulation in the treatment of pain in neurologic disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology.* Jan 12 2010; 74(2): 173-6. PMID 20042705
34. Wu LC, Weng PW, Chen CH, et al. Literature Review and Meta-Analysis of Transcutaneous Electrical Nerve Stimulation in Treating Chronic Back Pain. *Reg Anesth Pain Med.* May 2018; 43(4): 425-433. PMID 29394211
35. Jalalvandi F, Ghasemi R, Mirzaei M, et al. Effects of back exercises versus transcutaneous electric nerve stimulation on relief of pain and disability in operating room nurses with chronic non-specific LBP: a randomized clinical trial. *BMC Musculoskelet Disord.* Mar 26 2022; 23(1): 291. PMID 35337314
36. Leemans L, Elma , Nijs J, et al. Transcutaneous electrical nerve stimulation and heat to reduce pain in a chronic low back pain population: a randomized controlled clinical trial. *Braz J Phys Ther.* 2021; 25(1): 86-96. PMID 32434666
37. Keskin EA, Onur O, Keskin HL, et al. Transcutaneous electrical nerve stimulation improves low back pain during pregnancy. *Gynecol Obstet Invest.* 2012; 74(1): 76-83. PMID 22722614
38. Jamison RN, Wan L, Edwards RR, et al. Outcome of a High-Frequency Transcutaneous Electrical Nerve Stimulator (hfTENS) Device for Low Back Pain: A Randomized Controlled Trial. *Pain Pract.* Jun 2019; 19(5): 466-475. PMID 30636101
39. Tseng PT, Zeng BY, Hsu CW, et al. The comparative evidence of efficacy of non-invasive brain and nerve stimulation in diabetic neuropathy: a systematic review and network meta-analysis. *J Neuroeng Rehabil.* Apr 19 2025; 22(1): 88. PMID 40253366
40. ElMeligie MM, Gomaa YS, Taha E, et al. Neuropathic Pain Relief Through Transcutaneous Electrical Neuromuscular Stimulation: Insights From a Systematic Review and Meta-Analysis of Clinical Evidence. *Biomed Res Int.* 2025; 2025: 5328365. PMID 41132422
41. Gossrau G, Whner M, Kuschke M, et al. Microcurrent transcutaneous electric nerve stimulation in painful diabetic neuropathy: a randomized placebo-controlled study. *Pain Med.* Jun 2011; 12(6): 953-60. PMID 21627767
42. Kaye AD, Allen KE, Shah SS, et al. Efficacy of Transcutaneous Electrical Nerve Stimulation in Management of Cancer Pain: a Meta Analysis. *Curr Pain Headache Rep.* Jan 04 2025; 29(1): 5. PMID 39754697
43. Amer-Cuenca JJ, Badenes-Ribera L, Bivi-Roig G, et al. The dose-dependent effects of transcutaneous electrical nerve stimulation for pain relief in individuals with fibromyalgia: a systematic review and meta-analysis. *Pain.* Aug 01 2023; 164(8): 1645-1657. PMID 36893318
44. Garca-Lpez H, Calle-Ortega F, Garca-Robles P, et al. Effectiveness of transcutaneous electrical nerve stimulation improves pain intensity, disability and quality of life in patients with fibromyalgia syndrome: a systematic review with meta-analysis. *Disabil Rehabil.* Dec 2024; 46(26): 6323-6333. PMID 38511391
45. Dailey DL, Rakel BA, Vance CGT, et al. Transcutaneous electrical nerve stimulation reduces pain, fatigue and hyperalgesia while restoring central inhibition in primary fibromyalgia. *Pain.* Nov 2013; 154(11): 2554-2562. PMID 23900134
46. Lauretti GR, Chubaci EF, Mattos AL. Efficacy of the use of two simultaneously TENS devices for fibromyalgia pain. *Rheumatol Int.* Aug 2013; 33(8): 2117-22. PMID 23423539
47. Jamison RN, Edwards RR, Curran S, et al. Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial. *J Pain Res.* 2021; 14: 2265-2282. PMID 34335055
48. Schneider MP, Tellenbach M, Mordasini L, et al. Refractory chronic pelvic pain syndrome in men: can transcutaneous electrical nerve stimulation help?. *BJU Int.* Jul 2013; 112(2): E159-63. PMID 23433012
49. Reichenbach S, Jni P, Hincapi CA, et al. Effect of transcutaneous electrical nerve stimulation (TENS) on knee pain and physical function in patients with symptomatic knee osteoarthritis: the ETRELKA randomized clinical trial. *Osteoarthritis Cartilage.* Mar 2022; 30(3): 426-435. PMID 34826572
50. Cherian JJ, Harrison PE, Benjamin SA, et al. Do the Effects of Transcutaneous Electrical Nerve Stimulation on Knee Osteoarthritis Pain and Function Last?. *J Knee Surg.* Aug 2016; 29(6): 497-501. PMID 26540652
51. Palmer S, Domaille M, Cramp F, et al. Transcutaneous electrical nerve stimulation as an adjunct to education and exercise for knee osteoarthritis: a randomized controlled trial. *Arthritis Care Res (Hoboken).* Mar 2014; 66(3): 387-94. PMID 23983090
52. Vance CG, Rakel BA, Blodgett NP, et al. Effects of transcutaneous electrical nerve stimulation on pain, pain sensitivity, and function in people with knee osteoarthritis: a randomized controlled trial. *Phys Ther.* Jul 2012; 92(7): 898-910. PMID 22466027
53. Chen WL, Hsu WC, Lin YJ, et al. Comparison of intra-articular hyaluronic acid injections with transcutaneous electric nerve stimulation for the management of knee osteoarthritis: a randomized controlled trial. *Arch Phys Med Rehabil.* Aug 2013; 94(8): 1482-9. PMID 23628378
54. Sawant A, Dadurka K, Overend T, et al. Systematic review of efficacy of TENS for management of central pain in people with multiple sclerosis. *Mult Scler Relat Disord.* May 2015; 4(3): 219-27. PMID 26008938
55. Amatya B, Young J, Khan F. Non-pharmacological interventions for chronic pain in multiple sclerosis. *Cochrane Database Syst Rev.* Dec 19 2018; 12(12): CD012622. PMID 30567012

56. Johnson MI, Mulvey MR, Bagnall AM. Transcutaneous electrical nerve stimulation (TENS) for phantom pain and stump pain following amputation in adults. *Cochrane Database Syst Rev.* Aug 18 2015; 8(8): CD007264. PMID 26284511
57. Martins-de-Sousa PH, Fidelis-de-Paula-Gomes CA, Pontes-Silva A, et al. Additional effect of transcutaneous electrical nerve stimulation in a therapeutic exercise program for sedentary with chronic neck pain: A double-blind randomized controlled trial. *Physiother Res Int.* Jan 2023; 28(1): e1978. PMID 36252091
58. Daz-Pulido B, Prez-Martín Y, Pecos-Martín D, et al. Efficacy of Manual Therapy and Transcutaneous Electrical Nerve Stimulation in Cervical Mobility and Endurance in Subacute and Chronic Neck Pain: A Randomized Clinical Trial. *J Clin Med.* Jul 23 2021; 10(15). PMID 34362029
59. Nazarzade N, Gen A, Konca C, et al. Transcutaneous electrical nerve stimulation is a promising novel non-pharmacological treatment alternative for mastalgia: A randomized clinical trial. *Agri.* Apr 2025; 37(2): 75-82. PMID 40257210
60. Boldt I, Eriks-Hoogland I, Brinkhof MW, et al. Non-pharmacological interventions for chronic pain in people with spinal cord injury. *Cochrane Database Syst Rev.* Nov 28 2014; 2014(11): CD009177. PMID 25432061
61. AlHabil Y, Al-Sayed K, Salameh A. Trigeminal neuralgia improvement following Transcutaneous Electrical Nerve Stimulation (TENS): a systematic review and meta-analysis. *BMC Neurol.* Jan 08 2025; 25(1): 13. PMID 39780062
62. De Giorgi I, Castroflorio T, Sartoris B, et al. The use of conventional transcutaneous electrical nerve stimulation in chronic facial myalgia patients. *Clin Oral Investig.* Jan 2017; 21(1): 275-280. PMID 27000071
63. de Castro-Carletti EM, Mgggenborg F, Dennett L, et al. Effectiveness of electrotherapy for the treatment of orofacial pain: A systematic review and meta-analysis. *Clin Rehabil.* Jul 2023; 37(7): 891-926. PMID 36594219
64. Serrano-Muoz D, Beltran-Alacreu H, Martn-Caro Álvarez D, et al. Effectiveness of Different Electrical Stimulation Modalities for Pain and Masticatory Function in Temporomandibular Disorders: A Systematic Review and Meta-Analysis. *J Pain.* Jun 2023; 24(6): 946-956. PMID 36801166
65. Ferreira AP, Costa DR, Oliveira AI, et al. Short-term transcutaneous electrical nerve stimulation reduces pain and improves the masticatory muscle activity in temporomandibular disorder patients: a randomized controlled trial. *J Appl Oral Sci.* 2017; 25(2): 112-120. PMID 28403351
66. Ahmed S, Plazier M, Ost J, et al. The effect of occipital nerve field stimulation on the descending pain pathway in patients with fibromyalgia: a water PET and EEG imaging study. *BMC Neurol.* Nov 12 2018; 18(1): 191. PMID 30419855
67. Takla MKN. Low-frequency high-intensity versus medium-frequency low-intensity combined therapy in the management of active myofascial trigger points: A randomized controlled trial. *Physiother Res Int.* Oct 2018; 23(4): e1737. PMID 30095858
68. Johnson MI, Paley CA, Jones G, et al. Efficacy and safety of transcutaneous electrical nerve stimulation (TENS) for acute and chronic pain in adults: a systematic review and meta-analysis of 381 studies (the meta-TENS study). *BMJ Open.* Feb 10 2022; 12(2): e051073. PMID 35144946
69. Gibson W, Wand BM, Meads C, et al. Transcutaneous electrical nerve stimulation (TENS) for chronic pain - an overview of Cochrane Reviews. *Cochrane Database Syst Rev.* Apr 03 2019; 4(4): CD011890. PMID 30941745
70. Davison P, Wilkinson R, Miller J, et al. A systematic review of using electrical stimulation to improve clinical outcomes after hip fractures. *Physiother Theory Pract.* Dec 2022; 38(12): 1857-1875. PMID 33890541
71. Lang T, Barker R, Steinlechner B, et al. TENS relieves acute posttraumatic hip pain during emergency transport. *J Trauma.* Jan 2007; 62(1): 184-8; discussion 188. PMID 17215752
72. Zhu Y, Feng Y, Peng L. Effect of transcutaneous electrical nerve stimulation for pain control after total knee arthroplasty: A systematic review and meta-analysis. *J Rehabil Med.* Nov 21 2017; 49(9): 700-704. PMID 28933513
73. Yang J, Zheng C, Zhang C, et al. Transcutaneous electrical nerve stimulation for pain relief after orthopedic surgery: a systematic review and meta-analysis of randomized controlled trials. *Minerva Anesthesiol.* Oct 2025; 91(10): 951-960. PMID 41211915
74. gren C, Varkey E, Wolf A, et al. High-frequency, high-intensity TENS compared to standard treatment with opioids for postoperative pain relief after laparoscopic cholecystectomy: A multicentre randomized controlled trial. *Eur J Pain.* Nov 2024; 28(10): 1772-1784. PMID 38943342
75. Hatefi F, Kazemi M, Manglian P, et al. The effects of cold compress and transcutaneous electrical nerve stimulation on the pain associated with chest tube removal among patients with coronary bypass grafting. *J Cardiothorac Surg.* May 25 2023; 18(1): 186. PMID 37231409
76. Ramanathan D, Saleh A, Klika AK, et al. The Use of Transcutaneous Electrical Nerve Stimulation After Total Knee Arthroplasty: A Prospective Randomized Controlled Trial. *Surg Technol Int.* Jul 25 2017; 30: 425-434. PMID 28537354
77. Parseliunas A, Paskauskas S, Kubiliute E, et al. Transcutaneous Electric Nerve Stimulation Reduces Acute Postoperative Pain and Analgesic Use After Open Inguinal Hernia Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial. *J Pain.* May 2021; 22(5): 533-544. PMID 33309784
78. Oztas B, Iyigun E. The effects of two different electrical stimulation methods on the pain intensity of the patients who had undergone abdominal surgery with a midline incision: Randomized controlled clinical trial. *Contemp Nurse.* 2019; 55(2-3): 122-138. PMID 31169066
79. Galli TT, Chiavegato LD, Liebano RE. Effects of TENS in living kidney donors submitted to open nephrectomy: a randomized placebo-controlled trial. *Eur J Pain.* Jan 2015; 19(1): 67-76. PMID 24831862
80. Tokuda M, Tabira K, Masuda T, et al. Effect of modulated-frequency and modulated-intensity transcutaneous electrical nerve stimulation after abdominal surgery: a randomized controlled trial. *Clin J Pain.* Jul 2014; 30(7): 565-70. PMID 24901753
81. Silva MB, de Melo PR, de Oliveira NM, et al. Analgesic effect of transcutaneous electrical nerve stimulation after laparoscopic cholecystectomy. *Am J Phys Med Rehabil.* Aug 2012; 91(8): 652-7. PMID 22311059
82. DeSantana JM, Walsh DM, Vance C, et al. Effectiveness of transcutaneous electrical nerve stimulation for treatment of hyperalgesia and pain. *Curr Rheumatol Rep.* Dec 2008; 10(6): 492-9. PMID 19007541
83. zbaş N, Ersoy E, Korkmaz M, et al. Effect of Transcutaneous Electrical Nerve Stimulation on Patients with Total Knee Replacement: A Randomized Controlled Trial. *Pain Manag Nurs.* Feb 2025; 26(1): 4-13. PMID 39153958
84. Forogh B, Aslanpour H, Fallah E, et al. Adding high-frequency transcutaneous electrical nerve stimulation to the first phase of post anterior cruciate ligament reconstruction rehabilitation does not improve pain and function in young male athletes more than exercise alone: a

- randomized single-blind clinical trial. *Disabil Rehabil.* Mar 2019; 41(5): 514-522. PMID 29117738
85. Tucker DL, Rockett M, Hasan M, et al. Does transcutaneous electrical nerve stimulation (TENS) alleviate the pain experienced during bone marrow sampling in addition to standard techniques? A randomised, double-blinded, controlled trial. *J Clin Pathol.* Jun 2015; 68(6): 479-83. PMID 25759407
 86. Binny J, Joshua Wong NL, Garga S, et al. Transcutaneous electric nerve stimulation (TENS) for acute low back pain: systematic review. *Scand J Pain.* Apr 24 2019; 19(2): 225-233. PMID 30849052
 87. Koukoulithras I, Stamouli A, Kolokotsios S, et al. The Effectiveness of Non-Pharmaceutical Interventions Upon Pregnancy-Related Low Back Pain: A Systematic Review and Meta-Analysis. *Cureus.* Jan 30 2021; 13(1): e13011. PMID 33728108
 88. Arik MI, Kiloatar H, Aslan B, et al. The effect of TENS for pain relief in women with primary dysmenorrhea: A systematic review and meta-analysis. *Explore (NY).* 2022; 18(1): 108-113. PMID 32917532
 89. Han S, Park KS, Lee H, et al. Transcutaneous electrical nerve stimulation (TENS) for pain control in women with primary dysmenorrhoea. *Cochrane Database Syst Rev.* Jul 22 2024; 7(7): CD013331. PMID 39037764
 90. Guy M, Foucher C, Juhel C, et al. Transcutaneous electrical neurostimulation relieves primary dysmenorrhea: A randomized, double-blind clinical study versus placebo. *Prog Urol.* Jul 2022; 32(7): 487-497. PMID 35249825
 91. Platon B, Thrn SE, Mannheimer C, et al. Effects of high-frequency, high-intensity transcutaneous electrical nerve stimulation versus intravenous opioids for pain relief after hysteroscopy: a randomized controlled study. *Obstet Gynecol Sci.* Sep 2020; 63(5): 660-669. PMID 32717773
 92. Lisn JF, Amer-Cuenca JJ, Piquer-Mart S, et al. Transcutaneous Nerve Stimulation for Pain Relief During Office Hysteroscopy: A Randomized Controlled Trial. *Obstet Gynecol.* Feb 2017; 129(2): 363-370. PMID 28079781
 93. Wu J, Lim S, Scott A, et al. Transcutaneous Electric Nerve Stimulation for Analgesia During Outpatient Endometrial Biopsy: A Randomized Controlled Trial. *Obstet Gynecol.* Jan 01 2025; 145(1): e14-e23. PMID 39575620
 94. Deussen AR, Ashwood P, Martis R, et al. Relief of pain due to uterine cramping/involution after birth. *Cochrane Database Syst Rev.* Oct 20 2020; 10(10): CD004908. PMID 33078388
 95. Thuvarakan K, Zimmermann H, Mikkelsen MK, et al. Transcutaneous Electrical Nerve Stimulation As A Pain-Relieving Approach in Labor Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Neuromodulation.* Aug 2020; 23(6): 732-746. PMID 32691942
 96. Lopez-Campos E, Soto-Gonzalez M, Alonso-Calvete A, et al. Effects of transcutaneous electric nerve stimulation on pain after episiotomy. A systematic review and meta-analysis. *Heliyon.* Jan 15 2025; 11(1): e41577. PMID 39850434
 97. Kurata NB, Ghatnekar RJ, Mercer E, et al. Transcutaneous Electrical Nerve Stimulation for Post-Cesarean Birth Pain Control: A Randomized Controlled Trial. *Obstet Gynecol.* Aug 01 2022; 140(2): 174-180. PMID 35852266
 98. Sabanci Baransel E, Barut S, Uar T. The Effects of Transcutaneous Electrical Nerve Stimulation Applied in the Early Postpartum Period After Cesarean Birth on Healing, Pain, and Comfort. *J Midwifery Womens Health.* 2024; 69(5): 681-688. PMID 38470299
 99. Kayman-Kose S, Arioz DT, Toktas H, et al. Transcutaneous electrical nerve stimulation (TENS) for pain control after vaginal delivery and cesarean section. *J Matern Fetal Neonatal Med.* Oct 2014; 27(15): 1572-5. PMID 24283391
 100. Bez Surez A, Martn Castillo E, Garca Andjar J, et al. Evaluation of the effectiveness of transcutaneous nerve stimulation during labor in breech presentation: a case series. *J Matern Fetal Neonatal Med.* Jan 2021; 34(1): 24-30. PMID 30654675
 101. Njogu A, Qin S, Chen Y, et al. The effects of transcutaneous electrical nerve stimulation during the first stage of labor: a randomized controlled trial. *BMC Pregnancy Childbirth.* Feb 24 2021; 21(1): 164. PMID 33627077
 102. Goldman AR, Porsch L, Hintermeister A, et al. Transcutaneous Electrical Nerve Stimulation to Reduce Pain With Medication Abortion: A Randomized Controlled Trial. *Obstet Gynecol.* Jan 01 2021; 137(1): 100-107. PMID 33278292
 103. Henkel A, Cahill EP, Chavez S, et al. Transcutaneous electrical nerve stimulation (TENS) for pain control during first-trimester procedural abortion: A blinded randomized controlled trial. *Contraception.* Sep 2025; 149: 110955. PMID 40381673
 104. Butera KA, George SZ, Borsa PA, et al. Prolonged Reduction in Shoulder Strength after Transcutaneous Electrical Nerve Stimulation Treatment of Exercise-Induced Acute Muscle Pain. *Pain Pract.* Nov 2018; 18(8): 954-968. PMID 29505689
 105. Chesterton LS, Lewis AM, Sim J, et al. Transcutaneous electrical nerve stimulation as adjunct to primary care management for tennis elbow: pragmatic randomised controlled trial (TATE trial). *BMJ.* Sep 02 2013; 347: f5160. PMID 23999980
 106. Dai D, Fernandes J, Kim H, et al. Comparative Effectiveness of Transcutaneous Afferent Patterned Stimulation Therapy for Essential Tremor: A Randomized Pragmatic Clinical Trial. *Tremor Other Hyperkinet Mov (N Y).* 2023; 13: 38. PMID 37869579
 107. Isaacson SH, Peckham E, Tse W, et al. Prospective Home-use Study on Non-invasive Neuromodulation Therapy for Essential Tremor. *Tremor Other Hyperkinet Mov (N Y).* Aug 14 2020; 10: 29. PMID 32864188
 108. Lu C, Khosla D, Kent A, et al. Transcutaneous Afferent Patterned Stimulation for Essential Tremor: Real-World Evidence with Long Term Follow-Up. *Tremor Other Hyperkinet Mov (N Y).* 2023; 13: 29. PMID 37663529
 109. Brillman S, Khemani P, Isaacson SH, et al. Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson's Disease. *Tremor Other Hyperkinet Mov (N Y).* 2023; 13: 25. PMID 37637850
 110. McGough JJ, Sturm A, Cowen J, et al. Double-Blind, Sham-Controlled, Pilot Study of Trigeminal Nerve Stimulation for Attention-Deficit/Hyperactivity Disorder. *J Am Acad Child Adolesc Psychiatry.* Apr 2019; 58(4): 403-411.e3. PMID 30768393
 111. Singh RBH, VanderPluym JH, Morrow AS, et al. Acute Treatments for Episodic Migraine [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2020 Dec. (Comparative Effectiveness Review, No. 239.) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK566246/>. Accessed November 7, 2025.
 112. Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. *Headache.* Jul 2021; 61(7): 1021-1039. PMID 34160823
 113. Tassorelli C, Diener HC, Silberstein SD, et al. Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine. *Cephalalgia.* Oct 2021; 41(11-12): 1135-1151. PMID 33990161

114. Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition. *Cephalalgia*. May 2019; 39(6): 687-710. PMID 30806518
115. Chou DE, Shnayderman Yurakh M, Winegarner D, et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. *Cephalalgia*. Jan 2019; 39(1): 3-14. PMID 30449151
116. Hokenek NM, Erdogan MO, Hokenek UD, et al. Treatment of migraine attacks by transcutaneous electrical nerve stimulation in emergency department: A randomized controlled trial. *Am J Emerg Med*. Jan 2021; 39: 80-85. PMID 31983598
117. Domingues FS, Gayoso MV, Sikandar S, et al. Analgesic efficacy of a portable, disposable, and self-applied transcutaneous electrical nerve stimulation device during migraine attacks: A real-life randomized controlled trial. *Pain Pract*. Nov 2021; 21(8): 850-858. PMID 34013542
118. Schoenen J, Vandersmissen B, Jeanette S, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. *Neurology*. Feb 19 2013; 80(8): 697-704. PMID 23390177
119. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Rheumatol*. Feb 2020; 72(2): 220-233. PMID 31908163
120. American College of Obstetricians and Gynecologists (ACOG) Committee Opinion Number 766 on Approaches to Limit Intervention During Labor and Birth. February 2019 (reaffirmed 2025). <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/Approaches-to-Limit-Intervention-During-Labor-and-Birth>. Accessed November 7, 2025.
121. Benzon HT, Connis RT, De Leon-Casasola OA, et al. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. *Anesthesiology*. Apr 2010; 112(4): 810-33. PMID 20124882
122. Chou R, Gordon DB, de Leon-Casasola OA, et al. Management of Postoperative Pain: A Clinical Practice Guideline From the American Pain Society, the American Society of Regional Anesthesia and Pain Medicine, and the American Society of Anesthesiologists' Committee on Regional Anesthesia, Executive Committee, and Administrative Council. *J Pain*. Feb 2016; 17(2): 131-57. PMID 26827847
123. National Cancer Institute. Pain (PDQ)-Health Professional Version. 2025. https://www.cancer.gov/about-cancer/treatment/side-effects/pain/pain-hp-pdq#_3. Accessed November 7, 2025.
124. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain. Version 2.2025. https://www.nccn.org/professionals/physician_gls/pdf/pain.pdf. Accessed November 7, 2025.
125. National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management [NG59]. 2016 (last updated 2020); <https://www.nice.org.uk/guidance/NG59>. Accessed November 6, 2025.
126. National Institute for Health and Care Excellence (NICE). Osteoarthritis in over 16s: diagnosis and management [NG226]. 2022. <https://www.nice.org.uk/guidance/ng226>. Accessed November 5, 2025.
127. National Institute for Health and Care Excellence (NICE). Intrapartum care [NG235]. 2023; <https://www.nice.org.uk/guidance/ng235>. Accessed November 7, 2025.
128. North American Spine Society. Diagnosis and Treatment of Low Back Pain. 2020. <https://www.spine.org/Portals/0/assets/downloads/ResearchClinicalCare/Guidelines/LowBackPain.pdf>. Accessed November 7, 2025.
129. Bono CM, Ghiselli G, Gilbert TJ, et al. An evidence-based clinical guideline for the diagnosis and treatment of cervical radiculopathy from degenerative disorders. *Spine J*. Jan 2011; 11(1): 64-72. PMID 21168100
130. McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. *Osteoarthritis Cartilage*. Mar 2014; 22(3): 363-88. PMID 24462672
131. Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. *Osteoarthritis Cartilage*. Nov 2019; 27(11): 1578-1589. PMID 31278997
132. Makkad B, Heinke TL, Sherifdeen R, et al. Practice Advisory for Postoperative Pain Management of Thoracic Surgical Patients: Executive Summary: A Report From the Society of Cardiovascular Anesthesiologists. *J Cardiothorac Vasc Anesth*. Apr 2025; 39(4): 880-888. PMID 39864980
133. World Health Organization. WHO guideline for non-surgical management of chronic primary low back pain in adults in primary and community care settings. December 2023. <https://www.who.int/publications/i/item/9789240081789>. Accessed November 7, 2025.
134. Centers for Medicare & Medicaid. National Coverage Determination (NCD) for Transcutaneous Electrical Nerve Stimulators (TENS) (280.13). 2012; <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=354&>. Accessed November 5, 2025.
135. Centers for Medicare & Medicaid. Decision Memo for Transcutaneous Electrical Nerve Stimulation for Chronic Low Back Pain (160.27). 2012; <https://www.cms.gov/medicare-coverage-database/details/nca-details.aspx?NCAId=256&DocID=CAG-00429N&NCDId=63&ncdver=2&bc=gAAAABAAAA&d>. Accessed November 7, 2025.
136. Centers for Medicare and Medicaid. National Coverage Determination (NCD) for Assessing Patient's Suitability for Electrical Nerve Stimulation Therapy (160.7.1). 2006; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=63&ncdver=2&DocID=160.7.1&bc=gAAAABAAAA&>. Accessed November 4, 2025.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
September 2012	New policy	
December 2013	Replace policy	Policy updated with literature review, references 22, 24, 26, 32 35, 36 & 54 added. Policy statements are unchanged.
June 2014	Replace policy	Policy updated with literature review; References 1, 26-28, 3135, 45-48, 50-52 added; last policy statement revised to specifically list use of TENS in prevention of migraine headaches as not medically necessary.
June 2015	Replace policy	Policy updated with literature review. References 33, 43, and 45-46 added, and references 55-56 updated; policy statements unchanged.
June 2016	Replace policy	Policy updated with literature review through October 12, 2015 references 33-34, 50, and 52 added. Policy statements unchanged.
March 2018	Replace policy	Policy updated with literature review through September 12, 2017; references 33, 39-40, 49, and 55 added. Policy statements unchanged except "not medically necessary, corrected to "investigational, due to 510(k) status.
March 2019	Replace policy	Policy updated with literature review through September 18, 2018; references 25, 27-28, 51, and 63 added; references 72-74 updated. Policy statements unchanged.
March 2020	Replace policy	Policy updated with literature review through September 7, 2019, references added. Policy statements unchanged.
March 2021	Replace policy	Policy updated with literature review through October 7, 2020, references added. Policy statements unchanged.
March 2022	Replace policy	Policy updated with literature review through November 10, 2021, references added. Investigational policy statements for the use of specific TENS devices for essential tremor and ADHD indications added to policy.
March 2023	Replace policy	Policy updated with literature review through September 19, 2022, references added. Policy statements unchanged.
March 2024	Replace policy	Policy updated with literature review through September 27, 2023, references added. Removed outdated clinical input. Separated out evidence on migraine from the chronic pain and acute pain sections. Added new policy statement to clarify that TENS is investigational for both prevention and treatment of migraine headache. Other policy statements unchanged.
March 2025	Replace policy	Policy updated with literature review through October 15, 2024; references added. Separated action tremor associated with Parkinson disease from essential tremor. Added new policy statements to differentiate TAPS as investigational for both essential tremor and action tremor associated with Parkinson disease. Updated title to incorporate TAPS. Other policy statements unchanged.
March 2026	Replace policy	Policy updated with literature review through November 7, 2025; references added. Policy statements unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.